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Background: Hepatitis C is a blood-borne virus primarily spread through sharing of 
drug-injecting equipment. Approximately 150 million people worldwide and 230,000 Australians 
are living with chronic hepatitis C infection. In March 2016, the Australian government began 
subsidizing direct acting antivirals (DAAs) for the treatment of hepatitis C, which are highly 
effective (95% cure rate) and have few side effects. However, there is limited evidence to inform 
the provision of adherence support to people with hepatitis C on DAAs including the level of 
medication adherence required to achieve a cure.
Methodology: In February 2016, a steering committee comprising four authors convened an 
expert panel consisting of six hepatology nurses, a hepatologist, a pharmacist, a consumer with 
hepatitis C and treatment experience, and a consumer advocate. The expert panel focused on the 
following criteria: barriers and enablers to DAA adherence; assessment and monitoring of DAA 
adherence; components of a patient-centered approach to DAA adherence; patients that may 
require additional adherence support; and interventions to support DAA adherence. The resultant 
guidelines underwent three rounds of consultation with the expert panel, Australasian Hepatology 
Association (AHA) members (n=12), and key stakeholders (n=7) in June 2016. Feedback was 
considered by the steering committee and incorporated if consensus was achieved.
Results: Twenty-four guidelines emerged from the evidence synthesis and expert panel 
discussion. The guidelines focus on the pretreatment assessment and education, assessment of 
treatment readiness, and monitoring of medication adherence. The guidelines are embedded in 
a patient-centered approach which highlights that all patients are at risk of nonadherence. The 
guidelines recommend implementing interventions focused on identifying patients’ memory 
triggers and hooks; use of nonconfrontational and nonjudgmental language by health profes-
sionals; and objectively monitoring adherence.
Conclusion: These are the first guidelines to support patients and health professionals in the 
delivery of clinical care by identifying practical adherence support interventions for patients 
taking DAAs.
Keywords: nursing, adherence, best practice, nursing support, hepatitis C treatment
Introduction
Infection with hepatitis C virus and the resultant liver disease is a global public 
health issue affecting approximately 150 million people worldwide and an estimated 
230,470 Australians.1 Australia is in the unique position, globally, to have diagnosed 
approximately 75% of people affected by hepatitis C; however, treatment rates remain 
correspondence: Jacqueline A richmond
Viral hepatitis research Program, 
Australian research centre in sex, 
health and society, la Trobe University, 
215 Franklin street, Melbourne, 
Vic 3000, Australia
Tel +61 488 662 268
email j.richmond@latrobe.edu.au 
Journal name: Patient Preference and Adherence
Article Designation: Original Research
Year: 2016
Volume: 10
Running head verso: Richmond et al
Running head recto: AHA consensus guidelines on adherence support
DOI: http://dx.doi.org/10.2147/PPA.S117757
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
8.
25
.7
9.
83
 o
n 
13
-S
ep
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Preference and Adherence 2016:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2480
richmond et al
low by global standards with only 26% having received 
treatment and the proportion of people being treated each 
year remaining unchanged, at 1%, since 2007.2
On March 1, 2016, Australia became one of the few 
developed countries to publicly subsidise curative direct act-
ing antivirals (DAAs) regimens for all people with hepatitis C 
infection. The Australian health care system is operated by 
both government and private institutions. The universal health 
care system, Medicare, is administered by the Australian 
Federal Government and coexists with a private health sys-
tem. The federal government also funds the Pharmaceutical 
Benefits Scheme (PBS) which subsidises a range of prescrip-
tion medications. The listing of the DAAs on the PBS ensures 
that anyone diagnosed with hepatitis C regardless of their 
stage of liver disease can access DAAs. Due to their high 
cost and the potential (low) risk of developing viral resistance 
after unsuccessful cure, the Australasian Hepatology Asso-
ciation (AHA) strongly advocates that every effort be made 
to ensure that all patients commenced on a DAA regimen be 
given the optimal chance of cure on their first attempt. High 
adherence is a process, not an isolated event, and it is critical 
that adherence support is integrated into the practice of all 
members of the interdisciplinary team.
Experience gained from the treatment of chronic infectious 
diseases such as the human immunodeficiency virus (HIV) 
and tuberculosis has shown that even the most motivated 
patient is susceptible to waning medication adherence.3 
Medication adherence is a complex multidimensional phe-
nomenon influenced by numerous factors. The World Health 
Organisation (WHO) suggests that adherence is influenced by 
a complex interaction of five domains: social and economic 
system, health care system, disease-related factors, treatment-
related factors, and individual factors.3 Multiple strategies 
and/or interventions are necessary to address adherence to 
DAA regimens by people with hepatitis C infection.
There is limited evidence to assist the interdisciplinary 
team, including nurses, general practitioners (GPs), medical 
specialists, and community and peer workers, to provide 
adherence support to people with hepatitis C taking DAAs. 
The purpose of this article is to synthesize evidence and 
expert opinion on the provision of adherence support through 
discussion with an expert panel. The outcome is a series of 
consensus guidelines for implementation in the hepatitis C 
clinical setting (Box 1).
A Consensus Statement 20164 outlines the clinical man-
agement of hepatitis C DAA treatment. The AHA Consen-
sus Guidelines on the Provision of Adherence Support for 
People with Hepatitis C on DAAs (2016) support the clinical 
recommendations made in the consensus statement.4 The two 
Box 1 consensus guidelines
 1. Optimal adherence to the hepatitis c DAAs is yet to be 
determined. Therefore, it is recommended that every effort is 
made to support patients to be 100% adherent to DAAs.
 2. The patient-centered approach underpins the delivery of DAA 
adherence support.
 3. All patients are at risk of nonadherence (intentional and/or 
unintentional).
	4.	 Patients	benefit	from	receiving	holistic	care	from	members	of	the	
interdisciplinary team.
 5. All patients should have the opportunity to engage in 
a pretreatment assessment with a health professional 
knowledgeable about hepatitis c.
 6. All patients should have the opportunity to discuss their 
readiness to commence DAA treatment with a health 
professional knowledgeable about hepatitis c.
 7. The decision to commence DAA treatment is shared between 
the patient with hepatitis c and their treating clinician.
 8. Where possible, people with hepatitis c should have the 
opportunity to choose the clinical setting where they access 
DAA treatment (excluding patients with complex comorbidities, 
such as, but not limited, to cirrhosis).
 9. Pretreatment education should adopt a patient-centered approach 
incorporating the patient’s health literacy and cultural needs.
 10. Using a patient-centered approach pretreatment education should 
include a discussion about harm minimization strategies to reduce 
the risk of reinfection.
	11.	The	“teach-back”	method	could	be	used	to	confirm	that	the	patient	
has understood the information provided during the education 
session.
 12. health professionals and patients should identify possible factors 
that may impact on adherence prior to the patient commencing 
treatment.
 13. health professionals should support patients to select and implement 
an individualized adherence support strategy (incorporating memory 
triggers and hooks).
 14. A patient-centered approach should be used to assess and implement 
adherence support interventions.
 15. When exploring nonadherence with patients, health professionals 
should use nonconfrontational and nonjudgmental language.
 16. Using “normalization” and “gentle assumption” interviewing 
techniques can improve the validity of patient responses when 
exploring nonadherence.
 17. health professionals should adopt a shared decision-making 
approach with the patient when devising the care plan including the 
most appropriate education and adherence support strategies.
 18. Tools to assess and support medication adherence include visual 
analogue scales, pharmacy data, pill counts, and DOT.
 19. Patients who would like to access their DAA treatment through 
a community pharmacy should communicate with their preferred 
pharmacists about their capacity to supply the medication.
 20. Patients should be encouraged to communicate with their preferred 
pharmacists about how much time is required to order a repeat 
prescription.
	21.	The	patient	should	be	encouraged	to	document	the	first	day	they	
start taking DAA treatment to ensure that on-treatment and off-
treatment monitoring is scheduled appropriately.
 22. Medication adherence may be supported by feedback from pathology 
results, although this has not been validated as an adherence 
assessment tool.
(Continued)
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documents are intended to be used in conjunction to promote 
patient adherence to DAAs.
Methodology
In February 2016, a steering committee comprising four 
authors convened an expert panel on behalf of the AHA. 
The expert panel consisted of six hepatology nurses, a 
hepatologist, a GP with experience on hepatitis C treatment, 
a tertiary hospital-based pharmacist, an individual with per-
sonal experience on hepatitis C and DAA treatment, and a rep-
resentative of Hepatitis Australia. An evidence-based briefing 
document providing an overview of hepatitis C and adherence 
support was circulated to the expert panel 1 week prior to the 
meeting. The meeting sought to achieve consensus through 
group discussion on the following questions:
•	 What are the facilitators and barriers of adherence to 
DAAs in patients with hepatitis C?
•	 How is adherence in the DAA era defined? 
•	 What is the acceptable minimum number of tablets that 
should be taken?
•	 How can hepatology nurses assess adherence to DAAs – 
actual and projected adherence?
•	 How can we monitor adherence to DAAs?
•	 What are the key components of a patient-centered 
approach to DAA adherence?
•	 Are there patients who require additional adherence 
support?
	 Priority and special populations?
	 Which groups may need additional adherence 
support?
•	 How can hepatology nurses support adherence to DAA 
regimens (eg, interventions)?
The discussion was audio recorded and transcribed by a 
consultant medical writer. Familiarization of the transcript con-
tent was undertaken by the steering committee. Key concepts 
were identified and a preliminary draft document was prepared 
by the first author. The draft document was circulated to the 
expert panel, AHA member volunteers (n=12), and key stake-
holders (n=7) in three consultation phases. Each consultation 
phase was iterative and involved collecting feedback on the 
updated document and responses to an online survey. Feedback 
was considered by the steering committee and incorporated if 
consensus agreement was achieved. Where disagreement about 
the inclusion or wording of a guideline occurred, the steering 
committee made the final decision after in-depth discussion. 
The resulting consensus is presented.
Medication adherence in a chronic 
disease setting
A chronic disease is defined as an illness lasting longer than 
6 months. Medications that are prescribed to treat chronic dis-
ease aim to cure, optimize health, and/or prevent further health 
deterioration; however, treatment outcomes are only achieved 
if patients adhere to the medication regimen. Conversely, 
poor medication adherence reduces the potential for cure, 
increases the cost to public health, and reduces an individual’s 
productivity.5–9 Rates of medication adherence in chronic dis-
ease settings are well described in the literature. Adherence-
based studies in cardiovascular disease, diabetes, bipolar 
disorder, chronic obstructive airways disease, tuberculosis, 
and HIV report adherence rates between 30% and 92%.10–14 
The significant variation in reported medication adherence 
rates are related to methodological issues, specifically lack of 
consistency in defining and measuring adherence.15
The AHA has adopted the WHO definition of adherence: 
The extent to which a person’s behaviour – taking medica-
tion, following a diet, and/or executing lifestyle changes 
corresponds with agreed recommendations from a health 
care provider.3
Medication adherence relates to the way an individual 
takes a prescribed medication, including the use of the correct 
medication, the correct dose and time, duration and timely 
refill of a repeat prescription. “Adherence” implies that a 
patient is actively engaged in the decision-making process 
and has agreed to take the medication, whereas “compliance” 
suggests that a patient is a passive recipient of health care.3 
The AHA is promoting a patient-centered approach to the 
delivery of adherence support; therefore, “adherence” is the 
preferred term and is used throughout this document.
Nonadherence can be either intentional or unintentional. 
Intentional nonadherence refers to ceasing medication for 
prolonged periods of time and complete cessation without 
medical consultation or advice. In contrast, unintentional-
nonadherence refers to accidentally missing doses and/or not 
understanding the dosing as it was prescribed.16
Optimal adherence for hepatitis c DAA 
treatment
Research exploring adherence in the “real world” of 
hepatitis C DAAs is limited, and the level of adherence 
Box 1 (Continued)
 23. health professionals should ensure that patients have contact 
details for professional DAA treatment support including their 
general practitioner.
 24. The patient’s end-of-treatment outcome and self-reported level of 
adherence should be documented in the medical history.
Abbreviations: DAA, direct acting antiviral; DOT, directly observed treatment.
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required to achieve a sustained virological response (SVR) 
or cure remains unclear. Phase III trials that evaluated the 
effect of ledipasvir (LDV) and sofosbuvir (SOF) in 1900 
treatment-naïve and treatment-experienced patients with 
genotype 1 showed two cases of virological breakthrough on 
treatment. Both patients were suspected of nonadherence.17,18 
A further study of LDV/SOF with or without ribavirin 
(RBV) in patients with genotype 1 and cirrhosis, who 
were nonresponsive to previous protease inhibitor therapy, 
recorded medication adherence as either ,80% or .80%. 
In the LDV/SOF and RBV group, four patients had ,80% 
adherence; however, they all achieved an SVR (negative for 
hepatitis C virus 12 weeks posttreatment).19 Adherence was 
further evaluated in patients with hepatitis C mono-infection 
(n=20) and patients with HIV/hepatitis C coinfection (n=50). 
Tablets were counted which revealed that 40% of patients 
had missed one to four doses, 3% had missed five to eight 
doses, and 7% missed more than eight doses. Ninety-nine 
percent of patients (n=69) achieved an SVR.19
Further research suggests that while adherence to DAA 
regimens is high overall, it diminishes with longer treatment 
courses, particularly between weeks 8 and 12, among people 
with hepatitis C genotype 1 and people coinfected with 
hepatitis C and HIV.20,21 Older patients with a high number 
of comorbidities are also more likely to be nonadherent.22 
Missed doses and double dosing are the most commonly 
reported forms of nonadherence.23 Therefore, regularly 
assessing medication adherence is worthwhile.
Although DAAs are more potent, the risk of developing 
genotypic resistance exists.24 The role of resistant-associated 
substitutions (RAS) in DAA regimens is an active field 
of research. Baseline RAS are present in all patients with 
hepatitis C naïve to treatment. NS5A-treatment-emergent-
RAS in treatment-experienced patients can persist and create 
difficult retreatment challenges. The role of adherence in 
the development of RAS has not been directly studied but 
is likely to be a significant contributor.25
To realize the World Health Assembly’s goal of elimi-
nating hepatitis C by 2030,26 people with preexisting drug 
and alcohol and/or mental health issues, people in custodial 
settings, and Aboriginal and Torres Strait Islander people, 
who have previously had hepatitis C treatment deferred due 
to potential side effects and concerns about nonadherence, 
can be prioritized for DAA treatment.27 There is extensive 
evidence to support the treatment and management of patients 
with hepatitis C who currently inject drugs in interdisciplin-
ary, community-based settings and further evidence that 
adherence and response rates to interferon (IFN)-based 
treatment is similar to nondrug using populations.28–34 There 
is little evidence to support withholding hepatitis C treatment 
from people who inject drugs because of the potential for 
reinfection, as rates of reinfection following SVR are report-
edly low at ,5% per year even with the use of IFN-based 
treatments.35 Intensive case management can be particularly 
helpful to ensure that people who inject drugs remain in care 
and are adherent to medication regimens; some will require 
assistance with housing and treatment for comorbidities 
including psychiatric and substance use issues.24
Patient-centered approach
The AHA promotes a patient-centered approach to the 
delivery of hepatitis C DAA treatment. A patient-centered 
approach involves health professionals responding respect-
fully to every patient within their care, treating them as an 
individual, rather than as an illness or condition requiring 
management.36 This approach promotes the patient as an 
active partner with the health professional in their care. The 
care is focused on the individual’s personal health needs, 
wants, desires, and goals. Patient-centered care is a funda-
mental nursing concept, which underpins all nursing practice. 
The principle of patient-centered care guides the interpreta-
tion of the AHA’s consensus–based nursing guidelines37 and 
Practice Standards38 and is acknowledged in the Australian 
nursing codes, guidelines, decision-making frameworks, and 
standards for practice that guide nursing care.39
A patient-centered approach establishes the foundation 
to provide adherence support to people with hepatitis C 
on DAAs. An in-depth understanding of individualized 
adherence-related issues enables clinicians to ask appropri-
ate questions to discuss adherence-enhancing strategies with 
their patients.40 The pretreatment nursing assessment and the 
provision of on-treatment adherence support and monitoring 
must be individualized to overcome barriers and address the 
needs of the individual seeking care.
interdisciplinary approach
Worldwide, the team of health professionals caring for 
patients with hepatitis C is expanding to include hepatology 
nurses, nurse practitioners, nurses working in primary care, 
gastroenterologists, hepatologists and infectious diseases 
physicians, GPs and other medical practitioners (includ-
ing sexual health, and drug and alcohol physicians), social 
workers and psychologists, pharmacists, and peer workers. 
The expansion is likely to yield benefits in terms of patient 
education and support and the provision of adherence 
support. Consistent with the AHA’s consensus-based nursing 
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guidelines,37 the term interdisciplinary team incorporates dif-
ferent disciplines into a single assessment of, and consultation 
with, the patient. This approach promotes patient-centered 
care because the patient is involved in discussions and deci-
sions regarding their care and management. Interdisciplinary 
teams facilitate greater collaboration between health profes-
sionals and disciplines and theoretically deliver optimal 
patient outcomes.41
Assessing and supporting patient 
adherence with DAAs
Monitoring patient adherence and identifying individuals 
who need additional support is important in the DAA treat-
ment era. Such practice will ensure that the “real-world” data 
reflect the high cure rates achieved in clinical trials.42
There have been several qualitative studies exploring fac-
tors that influence patient adherence in the setting of pegylated 
IFN (PEG-IFN), RBV, and once-daily DAAs.40 Fear of hepa-
titis C-related morbidity and mortality and understanding that 
treatment could be curative were significant motivators for 
both uptake and completion of treatment.40,43 Obtaining infor-
mation during treatment on the likelihood of treatment success 
through viral load testing was identified in one study as an 
adherence motivator.44 While experience of hepatitis C-related 
stigma, often related to a history of injecting drug use, was 
also associated with medication adherence.42,45 Sublette 
et al42 found that participants reported feeling “unclean” and 
“embarrassed about divulging their status to doctors and den-
tists”, but this stigma disappeared once they had been cured of 
hepatitis C.42 The pervasive and negative impact of hepatitis 
C-related stigma on treatment adherence has highlighted the 
importance of the patient–health professional relationship, in 
terms of ameliorating the effects of stigma and building trust, 
which can improve adherence to care.46
Commitment of patients to nurse or clinician who treats 
hepatitis C virus infection is regularly identified as a strong 
facilitator of medication adherence, particularly in the setting 
of a collaborative relationship and open communication, which 
lead to honest dialogue about challenges to adherence.40,42 
In addition, social and emotional support provided by family 
and friends is critical to facilitating medication adherence, 
particularly in the setting of adverse treatment side effects. 
External support develops individuals’ self-efficacy and 
confidence to successfully engage in goal-directed behavior, 
and it has been shown to influence medication adherence 
across many chronic illnesses.47
People have devised ways to organize their daily 
routine to incorporate medication dosing into their lives 
in a “ritualistic” manner. However, changes in the daily 
routine such as being busy or traveling away from home 
can challenge adherence. Many routines focus on pairing 
administration of oral medications with meal times, and 
other personally important “hooks”. Other participants 
described a heightened sense of anxiety that drove their 
adherence to the treatment.23
While there is an expectation of improved adherence to the 
simplified DAA regimens, DAAs are now being prescribed to 
patients who would not have previously been offered PEG-
IFN-based regimens, with reduced monitoring and interaction 
with health professionals.42 Patient-related factors including 
forgetfulness, busy daily schedules and responsibility to 
family and friends, mental health issues, stigma, and low 
heath literacy will remain significant considerations when 
assessing the likelihood of patient adherence.48,49 Assessing 
and supporting patient adherence needs to be incorporated 
into clinical care by all health professionals involved in the 
treatment of people with hepatitis C infection. 
Pretreatment assessment
In the era of DAA treatment, encounters with patients will be 
significantly reduced once on treatment; therefore, the pre-
treatment assessment is a critical time to discuss medication 
adherence and develop or identify strategies that could be 
used to support adherence. Optimizing the chance of cure 
requires a high level of adherence to the DAA regimens and 
completing the full course of treatment.
Establishing a productive and supportive clinical rapport 
is vital to support the patient’s medication adherence. The 
pretreatment assessment could occur on the day the patient 
starts the treatment or weeks beforehand depending on how 
prepared the patient is to commence DAA treatment and how 
thoroughly they have been assessed, including assessment of 
liver diseases. The clinical pretreatment assessment involves 
exploring the patient’s medical and medication history, 
physical examination, virology investigations, and other 
investigations, including pathology and fibrosis assessment.4 
In addition, the pretreatment assessment should include 
exploration of the patient:
•	 Treatment readiness
•	 Pretreatment educational needs 
•	 Lifestyle particularly focused on facilitators and barriers 
to medication adherence.
Treatment readiness
The best time to start DAA treatment is when the patient is 
ready. It is more likely that DAA treatment will fail in patients 
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who are not prepared for treatment as a consequence of low 
motivation. A patient’s readiness to start treatment should 
be assessed prior to commencing, by a nurse, medical prac-
titioner, peer worker, and/or community worker. Adopting 
a patient-centered approach will mean the structure of a 
treatment readiness assessment will vary but fundamentally 
it should explore the patient:
•	 Educational needs about hepatitis C, disease progression, 
and DAA treatment
	 Understanding of their own clinical condition
•	 Beliefs about DAA treatment and the required level of 
adherence
•	 Lifestyle including potential facilitators and barriers to 
optimal adherence
•	 Preferences for where they access DAA treatment, for 
example, at their GP clinic or local community health 
center or tertiary hospital.
Individuals should be able to make an informed decision 
about when to start DAA treatment. The success of treatment 
is likely to be improved if the decision is shared between the 
patient and the treating clinician.50
Pretreatment education
It is important in the initial discussion to explore the 
patient’s level of hepatitis C knowledge and beliefs, and 
whether they have any concerns about DAA treatment. 
Pretreatment education should include consideration of the 
following topics:
•	 Hepatitis C disease and disease progression
•	 The need for DAA treatment
•	 How the DAAs work and possible side effects
•	 Relevant monitoring and surveillance testing during and 
after treatment completion
•	 Overview of medication adherence and importance of 
adherence to the DAAs
•	 Potential for drug–drug interactions, decreased efficacy 
of DAAs, and increased adverse effects due to prescribed 
and nonprescribed medications
•	 Strategies to support adherence
•	 Importance of discussing potential and actual adherence 
problems and the importance of completing the course 
of DAA treatment with a health professional and seeking 
adherence guidance promptly51
•	 Harm minimization strategies to prevent and reduce 
hepatitis C reinfection through injecting drug use, 
intranasal drug use, unsafe sexual practices, and cultural 
practices
•	 Disclosure and privacy issues related to hepatitis C and 
DAA administration; the impact of hepatitis C-related 
stigma and discrimination on DAA adherence.42
Underpinning the delivery of pretreatment education is 
the patient-centered approach. Individualizing the delivery of 
the education to the patient’s level of health literacy, English 
(or preferred first language) proficiency, and cultural back-
ground will enhance its effectiveness. Health professionals 
may consider using the “teach-back” method to confirm 
whether a patient understands what is being explained to them 
by a health professional.52 If the patient understands, they 
are able to “teach-back” the information accurately. Verbal 
information should be reinforced with electronic or written 
information produced by local hepatitis organizations and/or 
pharmaceutical companies that the patient can take home.
lifestyle assessment
Exploring an individual’s day-to-day routine prior to com-
mencing DAA treatment can assist the health professional 
and patient to identify potential facilitators and threats to 
medication adherence. Many people live unstructured lives, 
while others are well organized and regimented in their daily 
routines. However, everyone experiences unpredictable 
events that disrupt daily routines and, therefore, threaten 
medication adherence. 
A central goal of the pretreatment assessment is to explore 
the patient’s lifestyle to assist them to identify personally 
significant “hooks” or “triggers” that could be used to pair 
with the administration of medication. Asking the patient 
about the first thing they do when they wake up and/or the 
last thing they do before going to bed might be a useful way 
to start the conversation. Health professionals and patients 
should consider the following aspects of the patient’s life in 
terms of facilitating or threatening medication adherence:51
•	 Accommodation – stable or unstable housing?
•	 Employment – shift work, work-related travel?
•	 Financial – difficulty paying the dispensing fee at the 
pharmacy, or for the GP consultation?
•	 Drug and alcohol use – potential for disruption of daily 
routines and impact on medication adherence.53
•	 Hepatitis C-related stigma and discrimination – impact 
on the patient’s ability to use adherence support strate-
gies such as lifestyle routine, due to fear of disclosure of 
hepatitis C status.
•	 Prescribed and/or nonprescribed medications including 
herbal preparations and vitamins should be assessed dur-
ing every clinical encounter.
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•	 Depression – needs to be addressed prior to commencing 
DAA treatment.54
•	 Social life – weekday and weekend activities that may 
disrupt the daily routine?
•	 Cultural or health belief considerations that may impact 
on adherence.
•	 Eating habits – does the patient have regular eating, 
cooking, and shopping habits?
•	 Waking and sleeping habits.
Lifestyle assessment may require the inclusion of the 
patient’s family and/or friends to help document the daily rou-
tine and contingency plans to support medication adherence.
Interventions to support adherence
Supporting an individual’s DAA adherence encompasses 
interventions focused on the following:
•	 Patient
•	 Health professionals involved in the patient’s care
•	 Tools to support patient adherence
•	 Health system.
Patient adherence support interventions
There are a range of interventions that could be used to 
support patient adherence to DAAs (Table 1). Each interven-
tion needs to be considered in terms of a patient-centered 
approach; what works for one person may not work for 
another. Considering adherence interventions prior to 
commencing DAA treatment may assist patients to prioritize 
adherence and establish adherence-promoting routines. 
While it might be useful for the patient to have a separate 
reserve supply of medication at their workplace, or friend’s 
house or in the pocket of a bag, the expense of the hepatitis 
C DAAs precludes this backup system.
health professionals’ role in promoting 
adherence support
Research has consistently shown that health professionals’ 
assessment of adherence to HIV medication is overesti-
mated unless a validated assessment tool is used.55 Several 
studies have demonstrated the benefits of interdisciplinary 
care including nurses and pharmacists on patient adherence 
to hepatitis C treatment.56–58 While health professionals 
provide support which enables adherent behavior, they 
may inadvertently reinforce nonadherence by conveying 
displeasure when a patient discloses a missed dose(s).The 
concept of social desirability is well described in the adher-
ence literature, whereby patients underreport medication 
adherence to appease their clinicians. The use of nonconfron-
tational and nonjudgmental language provides an environ-
ment that is conducive to clinician–patient communication 
and allows for patient disclosure of nonadherent behavior and 
the reasons for missed medication. The way health profes-
sionals ask patients about missed doses plays a significant 
role in determining the validity of the answers provided.59 
Two interviewing techniques referred to as “normalization” 
and “gentle assumption” have been shown to improve the 
validity of patient responses when exploring sensitive topics. 
The technique involves normalizing the process of missed 
medication to reduce the patient’s shame and guilt, while 
also assuming that medications have been missed rather 
than asking directly.60 Table 2 outlines examples of normal-
izing and assumption strategies that could be used in patient 
interactions to support medication adherence.
Importantly, health professionals should routinely enquire 
about adherence to DAA regimens whenever they have con-
tact with the patient; a structured approach ensures patients 
are accustomed to thinking about adherence. Providing 
reassurance that they are not the only person who has 
forgotten to take their medication may provide patients with 
permission to fully discuss any potential adherence problems. 
While encouraging patients to monitor and document their 
missed doses may also empower the individual to identify 
the threats to their medication adherence. 
Tools to assess on-treatment adherence
There are several evidence-based behavioral interventions 
aimed at improving medication adherence.61 Strategies 
Table 1 Memory triggers and hooks to support medication 
adherence
strategic position of medication near an object or behavior that the 
patient does ritually every day:
•	 Between the toothbrush and toothpaste
•	 next to other medications or vitamins
•	 On the bed or pillow
•	 next to or on top of the alarm clock in the bedroom
•	 Beside the kettle or coffee jar
Automated reminders:
•	 setup a daily alarm on the patient’s smartphone or device
•	 Download a reminder application for the patient’s smartphone or 
device
•	 reminder notes on the fridge
•	 Medication dosing diary
Medication dispensing devices:
•	 Dosette box
•	 Daily assisted dosing
•	 Directly observed treatment
Note: Data from references 51 and 60.
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including implementing culturally appropriate education 
individualized to the patient’s level of health literacy, 
increasing social support, providing medication reminder 
tools, strengthening the patient–health care provider rela-
tionship, and offering directly observed treatment (DOT) 
have all been shown to be successful.55 A systematic review 
of patient adherence to IFN-based treatment for hepatitis C 
concluded that the highest adherence rates were reported in 
studies that used patient self-report strategies to measure 
adherence, whereas the lowest rates were reported in studies 
using pharmacy refill claims.62
The impact of DOT was explored in a randomized 
control trial (RCT) of 21 patients with hepatitis C receiving 
antiviral treatment, and methadone maintenance. The RCT 
demonstrated that patients who underwent DOT had greater 
success in achieving an SVR.63 DOT has a dual advantage of 
allowing assessment of adherence and an intervention that 
supports patients at risk of low adherence.64,65
Evidence-based strategies to assess medication adherence 
are also available and include the following:
•	 Structured self-reporting using visual analogue scales, 
although these measures tend to overestimate adherence. 
•	 Pharmacy data that indicates the frequency of refilling 
prescriptions (indirect confirmation).
•	 Electronic monitoring that records the opening and clos-
ing of the medication container.
•	 Pill counts that are commonly used in clinical trials.55
There are also a number of validated adherence assessment 
tools that could be implemented in clinical practice including 
the Adherence Starts with Knowledge-12 (ASK-12),66 the 
Brief Adherence Rating Scale (BARS),67 and the eight-item 
Morisky Medication Adherence Scale.68 Each tool is acces-
sible on the Internet and relatively easy to administer.
health system
In 2016, the Australian Government funded universal 
access to the hepatitis C DAAs and introduced systemic 
changes to medication prescribing and dispensing to sup-
port this. DAAs can now be prescribed by a broad range 
of medical practitioners under the section 85 PBS general 
listing and dispensed at community pharmacies. However, 
there have been initial community-based pharmacy imple-
mentation issues that may lead to the risk of unintended 
nonadherence. 
To avoid unintended nonadherence, patients need to 
be adequately informed and educated prior to, and during, 
treatment so they can manage any implementation issues 
associated with community dispensing. To mitigate any 
risk of nonadherence, nurses should discuss the potential for 
short delays in dispensing their medications and encourage 
them to plan ahead. It is also preferable for repeat prescrip-
tions to be dispensed by the same pharmacist (community 
or tertiary hospital based). If the patient maintains good 
communications with the pharmacist throughout the treat-
ment course, it will have the added benefit of providing an 
additional point of access to health care information relevant 
to their condition.
Monitoring treatment adherence 
and outcome
In order to ensure accurate monitoring of patients on 
treatment, health professionals need to determine the date 
the patient commenced the DAAs. The Australian Recom-
mendations for the Management of Hepatitis C indicate 
that a liver function test at week 4 of treatment is a suitable 
monitoring strategy.4 Adopting a patient-centered approach 
means the health professionals need to understand their 
patient’s on-treatment monitoring needs. Some patients may 
require additional motivation to remain adherent; hence, 
judicious use of viral load testing in certain circumstances 
may be warranted.
Health professionals must be aware that side effects to the 
DAAs have been reported. While the reported side effects 
tend to be few and mild, there is a potential for medication 
Table 2 linguistic strategies to support medication adherence in 
people with hepatitis c
Potentially problematic language Preferred language
have you been taking the medication 
the way it was prescribed?
it is very easy to forget to 
take medication and easy to 
forget that you have taken the 
medication. if you notice yourself 
doing that, can you write down if 
there was anything inconvenient 
about the timing of the dose?
have you been taking the medication 
the way i told you to?
Many people forget to take 
medication (normalization). in the 
weeks since we last met, how many 
doses do you think you may have 
missed? (gentle assumption)
Other	people	have	had	difficulty	
taking their medication … have 
you experienced any issues?
Are you taking the medication as 
directed on the bottle/packet?
Did you notice any problems 
with the doses being 
inconvenient	or	find	yourself	
missing any of them?
have you missed any doses? can you tell me how often you 
are taking the medication? how 
many tablets are you taking?
Note: Data from shea.60
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side effects to affect patient adherence. Health professionals 
should ensure that every patient is provided with their contact 
details and invited to initiate contact if they have any concerns 
about the medication (including concerns about drug-to-drug 
interactions with the DAAs or commencing new medica-
tions during the treatment course) or administration of the 
medication including missed or double doses.
Documenting the patient’s treatment outcome and their 
self-reported level of adherence at SVR 12 (12 weeks after 
treatment completion) is recommended. In the event of an 
unsuccessful course of treatment, it is important to ensure 
the patient receives appropriate ongoing care and support. 
The end-of-treatment time point also provides the health 
professional with an opportunity to evaluate and/or reflect 
on the impact of their clinical practice on the patient’s 
medication adherence.
Conclusion
The development of DAAs has revolutionized hepatitis C 
treatment and management. However, medications only work 
when people take them. The AHA Consensus Guidelines 
on the Provision of Adherence Support for People with 
Hepatitis C on DAAs were developed by an expert panel to 
guide health professionals in providing practical adherence 
support for patients with hepatitis C on DAAs. The document 
emphasizes that all patients are at risk of nonadherence and 
“treatment readiness” is a pivotal concept that influences 
subsequent adherent behavior.
The AHA Board intends to review this document bien-
nially, in order to incorporate the emergence of evidence 
and clinical developments, and to reflect the evolution 
of hepatitis C DAAs. The procedure used to update the 
guidelines will depend on the resources available at the 
time. For further information about the AHA refer to: www.
hepatologyassociation.com.au.
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